Sfoglia per AUTORE
HARMENBERG J
Collezione AOU Città della Salute di Torino

  

Items : 3

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9.
2021
AOU Città della Salute di Torino

Laubach JP; Moreb JS; Anderson KC; Raptis A; Mazumder A; Maisel C; Paner A; Alegre A; Hassoun H; Touzeau C; Hiemenz JW; Nadeem O; Leleu X; Rodriguez-Otero P; Cavo M; Bladé J; Larocca A; Oriol A; Richardson PG; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. in British journal of haematology / Br J Haematol. 2021 Jun;193(6):1105-1109. doi: 10.1111/bjh.17302. Epub 2021 Jan 6.
2021
AOU Città della Salute di Torino

Byrne C; Nordström E; Sonneveld P; Reeves B; Mellqvist UH; Plesner T; Voorhees PM; Bringhen S; Harmenberg J; Obermüller J; Richardson PG;

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. in The Lancet. Haematology / Lancet Haematol. 2020 May;7(5):e395-e407. doi: 10.1016/S2352-3026(20)30044-2. Epub 2020 Mar 23.
2020
AOU Città della Salute di Torino

Anderson K; Nordström E; Chauhan D; Byrne C; Zubair H; Paba-Prada C; Reeves B; Mellqvist UH; Plesner T; Voorhees P; Bringhen S; Richardson PG; Harmenberg J; Palumbo A; Sonneveld P;